Разрешен к применению с 1995 года.
Видео о
Купить в
COVID-19 
По алфавиту
F Donskov, K M Bennedsgaard, H Von Der Maase, N Marcussen, R Fisker, J J Jensen, P Naredi, M Hokland
Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survivalBr J Cancer. 2002 Jul 15;87(2):194-201.
F Lauria, D Raspadori, M A Ventura, D Rondelli, P L Zinzani, F Gherlinzoni, M C Miggiano, M Fiacchini, G Rosti, S Rizzi, S Tura
Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin’s lymphoma patients after autologous bone marrow transplantationBone Marrow Transplant. 1996 Jul;18(1):79-85.
F Y Ahmed, G A Leonard, R A’Hern, A E Taylor, A Lorentzos, H Atkinson, J Moore, M C Nicolson, P G Riches, M E Gore
A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanomaBr J Cancer. 1996 Oct;74(7):1109-13.
Fang J., Hu C., Hong M. et al.
Prophylactic Effects of Interleukin-2 Receptor Antagonists against Graft-versus-Host Disease Following Unrelated Donor Peripheral Blood Stem Cell Transplantation.Biol Blood Marrow Transplant 18:754-762, 2012.
Farace F, Mathiot C, Brandely M et al.
Phase I trial with recombinant interleukin-2 (rIL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gamma.Clin Exp Immunol. 1990 Nov;82(2):194-9. doi: 10.1111/j.1365-2249.1990.tb05426.x. PMID: 2122928; PMCID: PMC1535125.
Farag S.S., Caligiuri M.A.
The Therapeutic Use of Natural-Killer Cells in Hematological Malignancies.Immunotherapy of Cancer. Cancer Drug Discovery and Development. Humana Press. pp 415-432.
Farag SS, George SL, Lee EJ et al.
Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.Clin Cancer Res. 2002 Sep;8(9):2812-9.
Faridar et al. 
PDF
Alzheimer’s Research & Therapy. 2025. 17:146
Fatima U, Singh B, Subramanian K, Guptasarma P.
Insufficient (sub-native) helix content in soluble/solid aggregates of recombinant and engineered forms of IL-2 throws light on how aggregated IL-2 is biologically active.Protein J. 2012 Oct;31(7):529-43. doi: 10.1007/s10930-012-9429-2. Erratum in: Protein J. 2015 Aug;34(4):313. doi: 10.1007/s10930-015-9617-y. PMID: 22791129.
Fellner C.
Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use.P T. 2012 Sep;37(9):503-30. PMID: 23066344; PMCID: PMC3462607.
Feng Wang, Shuxian Wang, Bo He et al. PDF
International Immunopharmacology, 97, 107663. doi:10.1016/j.intimp.2021.10766
Fisher RI, Rosenberg SA, Fyfe G.
Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma.Cancer J Sci Am. 2000. — Feb;6 Suppl 1:S55-7. PMID: 10685660.
Fogli M., Mavilio D., Brunetta E. et al.
Lysis of endogenously infected CD4+ T cell blasts by rIL-2 activated autologous natural killer cells from HIV-infected viremic individuals.PLoS Pathog. 2008 Jul 11;4(7):e1000101. doi: 10.1371/journal.ppat.1000101.
Freeman ML, Clagett BM, Leskov K et al. PDF
Sci Adv. 2025 Dec 19;11(51):eaea4268. doi: 10.1126/sciadv.aea4268. Epub 2025 Dec 19. PMID: 41417900; PMCID: PMC12716389.
Fuentes E., Fuentes M., Alarcón M., Palomo I. PDF
Biomedical Sciences. An. Acad. Bras. Ciênc. 89 (1) • Mar 2017
В соответствии с п. 1 ст. 64 Федерального закона от 12.04.2010 № 61-ФЗ "Об обращении лекарственных средств" лекарственные препараты, находящиеся в обращении на территории Российской Федерации, подлежат мониторингу безопасности в целях выявления возможных негативных последствий их применения, предупреждения пациентов и их защиты от применения таких препаратов.